Nivolumab,Relatlimab
bms
['nivo', 'valent ,(-prevalent)']
 yes, but there still has to be meaningful diff significantly improving outcomes, especially if cost is &gt; negligible. if you can get equivalent outcomes w/nivo alone, let's not add more therapy because we're conditioned from marketing to think more treatment is better.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website